SAN-09611: Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease. The secondary study objective is to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 25
Maximum Age: 65
View:

• The participant is willing and able to provide written informed consent

• The participant is willing and able to provide appropriate photo identification

• Participants aged 25 to 65, inclusive

• Participants have been diagnosed with Huntington's Disease

• Patients must have numerical documentation of CAG repeats present in the Medical Record, along with a Huntington's Disease diagnosis.

• Pre-existing evidence of CAG repeats should be in the range of 40-60 repeats \*Preference (not required for enrollment): Patients to have different CAG repeats from each other but this is not essential.\*

Locations
United States
Massachusetts
Sanguine Biosciences, Inc.
RECRUITING
Woburn
Contact Information
Primary
Andrew C Frisina, M.S.
Afrisina@sanguinebio.com
9782394764
Time Frame
Start Date: 2023-03-14
Estimated Completion Date: 2025-02-28
Participants
Target number of participants: 5
Sponsors
Leads: Sanguine Biosciences
Collaborators: Hoffmann-La Roche

This content was sourced from clinicaltrials.gov